ES2072596T3 - Preparaciones de insulina que contienen acido nicotinico o nicotinamida. - Google Patents

Preparaciones de insulina que contienen acido nicotinico o nicotinamida.

Info

Publication number
ES2072596T3
ES2072596T3 ES91901711T ES91901711T ES2072596T3 ES 2072596 T3 ES2072596 T3 ES 2072596T3 ES 91901711 T ES91901711 T ES 91901711T ES 91901711 T ES91901711 T ES 91901711T ES 2072596 T3 ES2072596 T3 ES 2072596T3
Authority
ES
Spain
Prior art keywords
nicotinic acid
nicotinamide
preparations containing
insulin preparations
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91901711T
Other languages
English (en)
Inventor
Klavs Holger Jorgensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK654389A external-priority patent/DK654389D0/da
Priority claimed from DK7190A external-priority patent/DK7190D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2072596T3 publication Critical patent/ES2072596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

PREPARACIONES DE INSULINA QUE CONTIENEN ACIDO NICOTINICO O NICOTINAMIDA PREPARACIONES DE INSULINA QUE CONTIENEN NICOTINAMIDA O ACIDO NICOTINICO O UNA SAL DE LOS MISMOS QUE PRESENTAN PROPIEDADES FARMACOLOGICAS INTERESANTES.
ES91901711T 1989-12-21 1990-12-20 Preparaciones de insulina que contienen acido nicotinico o nicotinamida. Expired - Lifetime ES2072596T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK654389A DK654389D0 (da) 1989-12-21 1989-12-21 Laegemiddel
DK7190A DK7190D0 (da) 1990-01-10 1990-01-10 Laegemiddel

Publications (1)

Publication Number Publication Date
ES2072596T3 true ES2072596T3 (es) 1995-07-16

Family

ID=26063239

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91901711T Expired - Lifetime ES2072596T3 (es) 1989-12-21 1990-12-20 Preparaciones de insulina que contienen acido nicotinico o nicotinamida.

Country Status (10)

Country Link
US (1) US5382574A (es)
EP (1) EP0506792B1 (es)
JP (1) JP3122128B2 (es)
AT (1) ATE122567T1 (es)
AU (1) AU641721B2 (es)
CA (1) CA2070814A1 (es)
DE (1) DE69019534T2 (es)
DK (1) DK0506792T3 (es)
ES (1) ES2072596T3 (es)
WO (1) WO1991009617A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010417A1 (en) * 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CN101389650B (zh) * 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
AU2013203134B2 (en) * 2009-06-26 2016-05-12 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and an amino acid
EP2340033B1 (en) 2009-06-26 2013-10-09 Novo Nordisk A/S PREPARATION COMPRISING INSULIN, NICOTINAMIDE AND Arginine
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
JP2014501239A (ja) 2010-12-14 2014-01-20 ノヴォ ノルディスク アー／エス インスリン、ニコチンアミドおよびアミノ酸を含む製剤
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013130943A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013130935A1 (en) * 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
JP6224586B2 (ja) * 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9700599B2 (en) 2012-11-13 2017-07-11 Adocia Rapid-acting insulin formulation comprising a substituted anionic compound
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2015120457A1 (en) * 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
CN108026156A (zh) * 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
EP3341403B1 (en) * 2015-08-25 2022-01-05 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
JP7145849B2 (ja) 2016-09-29 2022-10-03 アレコル リミテッド 新規の製剤
US20190352374A1 (en) 2017-01-30 2019-11-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel igfr_like 2 receptor and uses thereof
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
CN112040928A (zh) 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵系统
EP3773472A1 (en) 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
US20210038506A1 (en) 2018-04-04 2021-02-11 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
TWI773009B (zh) 2019-12-11 2022-08-01 丹麥商諾佛 儂迪克股份有限公司 新穎之胰島素類似物及其用途
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2179384A (en) * 1937-04-05 1939-11-07 Univ Alberta Therapeutic composition and process of making it
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2793977A (en) * 1951-08-31 1957-05-28 Caspe Saul Compositions and method for reducing blood sugar concentration
DK116527B (da) * 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
GB1603639A (en) * 1978-05-26 1981-11-25 Haggar H Composition for application to the hair and scalp
CA1299102C (en) * 1987-06-15 1992-04-21 Steven G. Ayre Insulin potentiation therapy
US5155096A (en) * 1987-06-15 1992-10-13 Garcia Y Bellon Donato P Method for potentiation of a therapeutic agent
DE3850568D1 (de) * 1987-10-08 1994-08-11 Andor Bilas Stoffgemisch zur stabilisierung der stoffwechsel-lage.

Also Published As

Publication number Publication date
AU7047191A (en) 1991-07-24
ATE122567T1 (de) 1995-06-15
WO1991009617A1 (en) 1991-07-11
JP3122128B2 (ja) 2001-01-09
CA2070814A1 (en) 1991-06-22
DE69019534D1 (de) 1995-06-22
EP0506792B1 (en) 1995-05-17
DE69019534T2 (de) 1995-09-21
AU641721B2 (en) 1993-09-30
DK0506792T3 (da) 1995-10-09
EP0506792A1 (en) 1992-10-07
JPH05502234A (ja) 1993-04-22
US5382574A (en) 1995-01-17

Similar Documents

Publication Publication Date Title
ES2072596T3 (es) Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
HU9500245D0 (en) Injection and injection kit containing omeprazole and its analogs
DK0602794T3 (da) Insekticide N'-substituerede-N,N'-diacylhydraziner
DK0473333T3 (da) Modificeret polydextrose og fremgangsmåde til fremstilling heraf
DE3884055D1 (de) (1H-Azol-1-ylmethyl)-substituierte Benzotriazol-Derivate.
NO880558L (no) Pyridin-2,4- og 2,5-dikarboksylsyreamid, samt fremgangsmaate for fremstilling derav.
FR2659320B1 (fr) Liant geopolymerique fluoro-alumino-silicate et procede d'obtention.
ES2095940T3 (es) Procedimiento para la preparacion de derivados de s-acil-glutation y compuestos obtenidos por dicho procedimiento.
DK0589995T3 (da) Hidtil ukendte polypeptider og deres anvendelse
GB9126725D0 (en) Process
DK62288D0 (da) Substituerede 2,6-substituerede pyridinforbindelser og herbicide praeparater indeholdende disse forbindelser
DK0533790T3 (da) Hidtil ukendt saltform af 5-difluormethoxy-2-((3,4-dimethoxy-2-pyridyl)methylsulfinyl)-1H-benzimidazol
DE3877802D1 (de) Phenoxypropionsaeure-derivate, anwendbar als herbizide.
AU1281588A (en) N,n' or n',n' bis(aminoalkyl) thioureas, ureas or cyanoguanidines
KR900701798A (ko) 리파펜틴(Rifapentine) 할로겐산염류
EP0311385A3 (en) Optically active hydroxybenzylamine derivative, optically active amine-boron compound containing said derivative, and process for producing optically active compound by using said compound
EP0347818A3 (en) Process for preparing 3-pyrrolidinol
NO880557D0 (no) Pyridin-2,4- og 2,5-dikarboksylsyrederivater, samt fremgangsmaate for deres fremstilling.
DK62388A (da) Substituerede 2,6-substituerede pyridinforbindelser og herbicide praeparater indeholdende disse forbindelser
DE58903876D1 (de) Riboflavin-4'5'-cyclo-phosphorsaeureesterchlorid, dessen herstellung und verwendung zur herstellung von riboflavin-5'-phosphat (5'-fmn) bzw. dessen natriumsalz.
DK0482108T3 (da) Substituerede 2-imidazoliner samt fremstilling og anvendelse deraf
FI863549A0 (fi) (+)-6-klor-5,10-dihydro-5-/(1-metyl-4 -piperidinyl)-asetyl/-11h-dibenzo/b,e//1,4/diazepin-11-on, dess isolering och anvaendning saosom laekemedel.
HU913489D0 (en) New benzol(c)fenantridinium derivatives, medical preparations containing them and process for their production
NO910163D0 (no) Fremgangsmaate for fremstilling og anvendelse av pyridin-2,4- og 2,5-dikarboksylsyredi-(nitroksyalkyl)amid.
PT90281A (pt) Processo para a preparacao de composicoes insecticidas contendo 1-dimetilcarbamoil-1h-1,2,4,triazois substituidos nas posicoes 3 e 5

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506792

Country of ref document: ES